Which medicine is least appropriate for this patient for escalation of therapy in type 2 diabetes and heart failure?

• A. Metformin
• B. SGLT2 inhibitor
• C. GLP-1 receptor agonist
• D. Pioglitazone

Answer: (D)

In this scenario, the aim is to choose a diabetes medication that supports heart failure rather than worsens it. Medications are most favorable when they improve heart failure outcomes or at least do not promote fluid overload. Pioglitazone, a thiazolidinedione, tends to cause fluid retention and edema by promoting sodium and water retention, which can worsen congestion and heart failure symptoms. This makes it the least suitable option for escalation in a patient who has both type 2 diabetes and heart failure.

Metformin is generally safe in stable heart failure with adequate kidney function and remains a common first‑line choice. SGLT2 inhibitors have strong evidence showing reduced hospitalizations for heart failure and improved cardiovascular outcomes, so they are preferred in this context. GLP‑1 receptor agonists also offer cardiovascular benefits and can be used, particularly if SGLT2 inhibitors are not suitable, though their direct HF benefits are less pronounced than those of SGLT2 inhibitors.